Hossain M M, Begum M, Hossain M, Chowdhury M G, Begum R, Ahamed S, Shuvo F R
Dr Md Makbul Hossain, Consultant, Paediatric Cardiac Anesthesia and ICU, Dhaka Shishu Hospital, Dhaka, Bangladesh; E-mail: mmhossa
Mymensingh Med J. 2019 Jan;28(1):222-229.
Palonosetron is a new, potent and long-acting 5HT3-receptorsantagonist that had been approved by the FDA for use in postoperative nausea and vomiting (PONV) prophylaxis. The objective of this study was to investigate and compare the prophylactic effects of intravenously administered palonosetron, ondansetron and granisetron on prevention of postoperative nausea and vomiting after general anesthesia. This randomized double blind prospective clinical study was carried out in the Department of Anaesthesia, DMCH, Dhaka, Bangladesh from January 2014 to December 2015. A total of 102 patients who underwent laparoscopic cholecystectomy under general anesthesia, out of which patients who received Palonosetron were in Group A (n=34), patients who received Ondansetron were in group B (n=34) and patients who received Granisetron were in group C (n=34) and also the patients were selected randomly by lottery method. Statistical analyses of the results were obtained by using window based computer software devised with Statistical Packages for Social Sciences (SPSS-22). Nausea was found 3(8.8%) in group A, 8(23.5%) in group B and 6(17.6%) in group C. Vomiting was found 3(8.8%) in group A, 10(29.4%) in group B and 7(20.6%) in group C. Vomiting was significantly higher in group B compare with group A. For group B rescue anti-emetic injection motilon (metoclopramide hydrochloride) 5mg IV slowly was given. Palonosetron is effective prophylaxis against post operative nausea and vomiting.
帕洛诺司琼是一种新型、强效且长效的5-羟色胺3（5HT3）受体拮抗剂，已获美国食品药品监督管理局（FDA）批准用于预防术后恶心和呕吐（PONV）。本研究的目的是调查和比较静脉注射帕洛诺司琼、昂丹司琼和格拉司琼对预防全身麻醉后术后恶心和呕吐的效果。这项随机双盲前瞻性临床研究于2014年1月至2015年12月在孟加拉国达卡达卡医学院医院麻醉科进行。共有102例接受全身麻醉下腹腔镜胆囊切除术的患者，其中接受帕洛诺司琼的患者为A组（n = 34），接受昂丹司琼的患者为B组（n = 34），接受格拉司琼的患者为C组（n = 34），患者通过抽签法随机选择。结果的统计分析使用基于窗口的计算机软件，该软件由社会科学统计软件包（SPSS - 22）设计。A组有3例（8.8%）出现恶心，B组有8例（23.5%），C组有6例（17.6%）。A组有3例（8.8%）出现呕吐，B组有10例（29.4%），C组有7例（20.6%）。B组的呕吐发生率显著高于A组。对于B组，缓慢静脉注射5mg抢救用抗呕吐注射剂胃复安（盐酸甲氧氯普胺）。帕洛诺司琼对预防术后恶心和呕吐有效。
